Korean Circ J.  2014 Mar;44(2):74-75. 10.4070/kcj.2014.44.2.74.

Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist

• Chang SA

• KMID: 2223894
• DOI: http://doi.org/10.4070/kcj.2014.44.2.74

Abstract

No abstract available.

MeSH Terms

Endothelins*
Receptors, Endothelin*
Receptors, Endothelin

Reference

1. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358:1119–1123.

2. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371:2093–2100.

3. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012; 91:517–521.

4. Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012; 21:321–327.

5. Malenfant S, Neyron AS, Paulin R, et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013; 3:278–293.

6. Hong YM, Kwon JH, Choi S, Kim KC. Apoptosis and inflammation associated gene expressions in monocrotaline-induced pulmonary hypertensive rats after bosentan treatment. Korean Circ J. 2014; 44:97–104.

7. Gong S, Peng L, Yan B, et al. Bosentan reduces neuronal apoptosis following spinal cord ischemic reperfusion injury. Spinal Cord. 2013; [Epub ahead of print].

8. Bien S, Riad A, Ritter CA, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007; 67:10428–10435.

9. Peduto Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells. Br J Cancer. 2003; 88:788–795.